Eloxx Pharmaceuticals, Inc.
ELOXNASDAQHealthcareBiotechnology
Latest quote
$20.98
+$2.935 · +16.27%
ELOX company overview
Regular session · ET · Market data may be delayed.
Company profile
Company websiteEloxx Pharmaceuticals is a clinical-stage biopharmaceutical firm that specializes in developing therapeutic solutions through ribosome modulation. Its primary objective is to address rare and ultra-rare genetic diseases that arise from premature stop codons. The company's most advanced investigational compound, ELX-02, is currently progressing through Phase 2 clinical trials. This candidate is being evaluated for its potential to treat patients with cystic fibrosis and nephropathic cystinosis who possess diagnosed nonsense mutations. In addition to its lead program, Eloxx is actively pursuing several preclinical projects aimed at conditions like Alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis. The company also maintains various earlier-stage discovery initiatives focused on oncology. Eloxx Pharmaceuticals was established in 2013 and is headquartered in Watertown, Massachusetts.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Sumit Aggarwal
- Listed since
- Jun 9, 2026
- Employees
- 10
Market position
- Volume
- 93.39K
- 2.13× average
- Average volume
- 43.86K
- Average daily volume
- Market cap
- 72.08M USD
- Beta
- -9.95
- Market reference 1
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- -3.79M USD
- EV / EBITDA
- 0.77×
- Earnings yield
- -5341294.94%
- Free cash flow yield
- 0.00%
Profitability & efficiency
- Return on equity
- 50.35%
- Return on assets
- -113.76%
- Return on invested capital
- 59.03%
Financial health
- Current ratio
- 0.31×
- Altman Z-score
- -4.06
- Piotroski F-score
- 3 of 9
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Rating distribution
11 ratingsCorporate actions
Corporate action history
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jun 1, 2026 | 1:11 | — | — |
Stock split | Dec 2, 2022 | 1:40 | — | — |
Stock split | Dec 20, 2017 | 1:20 | — | — |
Stock split | Oct 21, 2013 | 1:100 | — | — |
Stock split | Oct 25, 1999 | 2:1 | — | — |
Effective Jun 1, 2026
1:11
Effective Dec 2, 2022
1:40
Effective Dec 20, 2017
1:20
Effective Oct 21, 2013
1:100
Effective Oct 25, 1999
2:1
ELOX peers
Continue in GoAI
Research ELOXresearch.disclaimer